Efficacy of Sumatriptan/Placebo versus Sumatriptan/Propofol Combination in Acute Migraine; a Randomized Clinical Trial
Archives of Academic Emergency Medicine,
Vol. 10 No. 1 (2022),
1 January 2022
,
Page e27
https://doi.org/10.22037/aaem.v10i1.1510
Abstract
Introduction: Migraine headaches can cause severe pain for patients and lead them to multiple visits to the emergency department (ED). This study aimed to evaluate the efficacy of propofol + sumatriptan combination in comparison with sumatriptan alone in the management of acute migraine headaches.
Methods: This triple-blind clinical trial involved patients who referred to two emergency departments with acute migraine headaches. Patients were randomly assigned to control (sumatriptan and placebo) or intervention (propofol and sumatriptan) groups for comparison of the efficacy and side effects of treatment.
Results: In this study, 60 patients were included whose mean age was 31±8.8 years, and headaches were more common among women. After 30 and 60 minutes from the beginning of treatment, the mean pain score reduction in the intervention group was significantly greater than that in the control group (p=0.012, p=0.024). In addition, the rate of chest tightness in the control group was significantly higher than the intervention group. The absolute risk reduction of adverse events (Chest tightness, Bradycardia, hypotension, and etc.), in patients with acute migraine headache taking propofol and sumatriptan treatment, was 32.18% (95% CI: 8.02 – 56.35).
Conclusions: This study supports the use of propofol for treatment of acute migraine headaches and shows that combining sumatriptan with propofol is more effective in relieving migraine headaches and the associated symptoms than using sumatriptan alone. However, more studies with longer follow-ups are still needed.
- Migraine disorders
- headache
- sumatriptan
- propofol
- pain management
How to Cite
References
Wu J, Davis‐Ajami ML, Kevin Lu Z. Impact of depression on health and medical care utilization and expenses in US adults with migraine: a retrospective cross sectional study. Headache: The Journal of Head and Face Pain. 2016; 56(7):1147-60.
Delavar Kasmaei H, Amiri M, Negida A, Hajimollarabi S, Mahdavi N. Ketorolac versus Magnesium Sulfate in Migraine Headache Pain Management; a Preliminary Study. Arch Acad Emerg Med. 2017; 5(1):e2.
Burch R. Antidepressants for preventive treatment of migraine. Curr Treat Options Neurol. 2019; 21(4):18.
Salmito MC, Duarte JA, Morganti LOG, Brandão PVC, Nakao BH, Villa TR, et al. Prophylactic treatment of vestibular migraine. Braz J Otorhinolaryngol. 2017; 83:404-10.
Cady R, Saper J, Dexter K, Manley HR. A Double‐Blind, Placebo‐Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With T x360 as Acute Treatment for Chronic Migraine. Headache: The Journal of Head and Face Pain. 2015; 55(1):101-16.
Deen M, Martinelli D, Pijpers J, Diener H-C, Silberstein S, Ferrari MD, et al. Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. Cephalalgia. 2019; 39(8):1058-66.
Khazaei M, Mir NHN, Aghdam FY, Taheri M, Ghafouri-Fard S. Effectiveness of intravenous dexamethasone, metoclopramide, ketorolac, and chlorpromazine for pain relief and prevention of recurrence in the migraine headache: a prospective double-blind randomized clinical trial. Curr J Neurol. 2019; 40:1029-33.
Mayans L, Walling A. Acute migraine headache: treatment strategies. Ann Fam Med. 2018; 97(4):243-51.
Deen M, Hougaard A, Hansen HD, Schain M, Dyssegaard A, Knudsen GM, et al. Association between sumatriptan treatment during a migraine attack and central 5-HT1B receptor binding. JAMA neurology. 2019; 76(7):834-40.
Jesani J, Simerson D. Pharmacologic management of acute migraines in the emergency department. Adv Emerg Nurs J. 2019; 41(2):150-62.
Sheridan DC, Hansen ML, Lin AL, Fu R, Meckler GD. Low-dose propofol for pediatric migraine: a prospective, randomized controlled trial. jem-journal. 2018; 54(5):600-6.
Cisewski DH, Motov SM. Essential pharmacologic options for acute pain management in the emergency setting. Turk J Emerg Med. 2019; 19(1):1-11.
Piatka C, Beckett RD. Propofol for treatment of acute migraine in the emergency department: a systematic review. Academic Emergency Medicine. 2020; 27(2):148-60.
Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci. 1993; 14(4):129-33.
Solomon S, Lipton RB, Newman LC. The site of common side effects of sumatriptan. Headache: The Journal of Head and Face Pain. 1997; 37(5):289-90.
Brar Y, Hosseini SA, Saadabadi A. Sumatriptan. StatPearls. Treasure Island (FL): StatPearls Publishing 2022.
Ron Walls RH, Marianne Gausche-Hill. Rosen's Emergency Medicine: Concepts and Clinical Practice. 9th ed. Philadelphia: Elsevier; 2017 March 9, 2017.
Kotani Y, Shimazawa M, Yoshimura S, Iwama T, Hara H. The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties. CNS Neurosci Ther. 2008; 14(2):95-106.
Marik PE. Propofol: therapeutic indications and side-effects. Current pharmaceutical design. 2004; 10(29):3639-49.
Folino TB, Muco E, Safadi AO, Parks LJ. Propofol. StatPearls. Treasure Island (FL): StatPearls Publishing.
Judith Tintinalli OJM, Donald Yealy, Garth Meckler, J. Stapczynski, David Cline, Stephen Thomas Toxicology, Opioids. In: Tintinalli JE, editor. Tintinalli's Emergency Medicine and Comprehensive Study Guide 1: Mc Graw Hill; 2020. p. 1234.
Roberts J. Roberts and Hedges’ Clinical Procedures in Emergency Medicine and Acute Care. Philadelphia: Elsevier; 2017 December 12, 2017. 1500 p.
Moshtaghion H, Heiranizadeh N, Rahimdel A, Esmaeili A, Hashemian H, Hekmatimoghaddam S. The efficacy of propofol vs. subcutaneous sumatriptan for treatment of acute migraine headaches in the emergency department: A double‐blinded clinical trial. Pain practice. 2015; 15(8):701-5.
Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache: The Journal of Head and Face Pain. 2000;40(3):224-30.
Soleimanpour H, Taheraghdam A, Ghafouri RR, Taghizadieh A, Marjany K, Soleimanpour M. Improvement of refractory migraine headache by propofol: case series. International Journal of Emergency Medicine. 2012; 5(1):19.
Meek R, Graudins A, McDonald M, McGannon D, Limm E. Comparing propofol with placebo for early resolution of acute migraine in adult emergency department patients: A double‐blind randomised controlled trial. Emerg Med Australas. 2020; 33(3): 465-472.
Alpay K, Ertas M, Orhan EK, Ustay DK, Lieners C, Baykan B. Diet restriction in migraine, based on IgG against foods: a clinical double-blind, randomised, cross-over trial. Cephalalgia : an international journal of headache. 2010;30(7):829-37.
Baker M, Naguib M. Propofol: The Challenges of Formulation. Anesthesiology. 2005;103:860-76.
Mitra B, Roman C, Mercier E, Moloney J, Yip G, Khullar K, et al. Propofol for migraine in the emergency department: A pilot randomised controlled trial. Emerg Med Australas. 2020; 32(4):542-7.
- Abstract Viewed: 755 times
- pdf Downloaded: 570 times